Association of metabolic risk factor clustering and all-cause mortality in adults with non-metabolic syndrome: the rural Chinese cohort study

  • Chengyi Han
  • Xuesong Jiang
  • Bingyuan Wang
  • Yongcheng Ren
  • Yang Zhao
  • Dongsheng HuEmail author
Original Article


Studies demonstrated an increased risk of death with aggregation of metabolic syndrome (MetS) components in the general population; however, the association is unclear in people with non-MetS. We aimed to explore the effect of aggregated metabolic risk factors on all-cause mortality in the non-MetS population. Questionnaire interviews and physical and blood biochemical factors for 13,749 adult participants were analyzed at baseline between July–August 2007 and July–August 2008. We followed up 11,604 participants (84.4%) between July–August 2013 and July–October 2014. Cox proportional-hazards regression produced multivariate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) to evaluate metabolic risk factor clustering at baseline for all-cause mortality at follow-up. During a mean of 5.93 years of follow-up, 742 deaths (508 males) occurred. With aggregated metabolic risk factors, mortality rate increased overall for male and female participants (p < 0.001). For all participants, adjusted HRs for death increased from 1.29 to 1.91 with increased number of metabolic risk factors; risk of death was increased with elevated blood pressure (BP), low high-density lipoprotein cholesterol (HDL-C) level, and high glucose level (HR 1.43 [95% CI 1.23–1.67], 1.17 [1.01–1.37], and 1.24 [1.06–1.45], respectively). A similar association was observed in males but not females, except for elevated BP. Mortality risk increases with aggregated metabolic risk factors except for females, and might be attributed to high BP, low HDL-C levels, and high glucose levels in the non-MetS Chinese population.


Cohort study Metabolic risk factor Metabolic syndrome Mortality 



The authors thank all the participants of the survey and all the survey staff.

Funding information

This study was supported by the National Natural Science Foundation of China (no. 81673260) and the Science and Technology Development Foundation of Shenzhen (nos. JCYJ2016030715570 and JCY20170412110537191).

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.


  1. 1.
    Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb. 2005;12(6):295–300. Scholar
  2. 2.
    Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J. 2007;28(7):857–64. Scholar
  3. 3.
    Thomas GN, Schooling CM, McGhee SM, Ho SY, Cheung BM, Wat NM, et al. Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study. Clin Endocrinol. 2007;66(5):666–71. Scholar
  4. 4.
    Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ (Clinical research ed). 2006;332(7546):878–82. CrossRefGoogle Scholar
  5. 5.
    Sun DL, Wang JH, Jiang B, Li LS, Li LS, Wu L, et al. Metabolic syndrome vs. its components for prediction of cardiovascular mortality: a cohort study in Chinese elderly adults. J Geriatr Cardiol: JGC. 2012;9(2):123–9. CrossRefPubMedGoogle Scholar
  6. 6.
    Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.
  7. 7.
    Liu L, Miura K, Fujiyoshi A, Kadota A, Miyagawa N, Nakamura Y, et al. Impact of metabolic syndrome on the risk of cardiovascular disease mortality in the United States and in Japan. Am J Cardiol. 2014;113(1):84–9.
  8. 8.
    Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709–16.
  9. 9.
    Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403–14.
  10. 10.
    Ghaem Maralani H, Tai BC, Wong TY, Tai ES, Li J, Wang JJ, et al. Metabolic syndrome and mortality in the elderly: a time-dependent association. Diabetes Res Clin Pract. 2013;99(2):209–16.
  11. 11.
    Mozaffarian D, Kamineni A, Prineas RJ, Siscovick DS. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med. 2008;168(9):969–78. Scholar
  12. 12.
    Akbaraly TN, Kivimaki M, Ancelin ML, Barberger-Gateau P, Mura T, Tzourio C, et al. Metabolic syndrome, its components, and mortality in the elderly. J Clin Endocrinol Metab. 2010;95(11):E327–32.
  13. 13.
    Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32.
  14. 14.
    Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769–78.CrossRefPubMedGoogle Scholar
  15. 15.
    Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Archives of InternalMedicine. 2004;164(10):1066–76. Scholar
  16. 16.
    Kadota A, Hozawa A, Okamura T, Kadowak T, Nakmaura K, Murakami Y, et al. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990-2000. Diabetes Care. 2007;30(6):1533–8.
  17. 17.
    Franks PW, Olsson T. Metabolic syndrome and early death: getting to the heart of the problem. Hypertension. 2007;49(1):10–2. Scholar
  18. 18.
    Chen WW, Gao RL, Liu LS, Zhu ML, Wang W, Wang YJ, et al. Report on cardiovascular disease (2016): abstract. Chin Circul J. 2017;32(6):521–30.
  19. 19.
    Bondy SJ, Victor JC, Diemert LM. Origin and use of the 100 cigarette criterion in tobacco surveys. Tob Control. 2009;18(4):317–23. Scholar
  20. 20.
    Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol. 2006;47(9):1741–53. CrossRefPubMedGoogle Scholar
  21. 21.
    Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–9.
  22. 22.
    Hong Y, Jin X, Mo J, Lin HM, Duan Y, Pu M, et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality--results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med. 2007;262(1):113–22.
  23. 23.
    Zambon S, Zanoni S, Romanato G, Corti MC, Noale M, Sartori L, et al. Metabolic syndrome and all-cause and cardiovascular mortality in an Italian elderly population: the Progetto Veneto Anziani (Pro.V.A.) Study. Diabetes Care. 2009;32(1):153–9. Scholar

Copyright information

© Research Society for Study of Diabetes in India 2018

Authors and Affiliations

  • Chengyi Han
    • 1
    • 2
  • Xuesong Jiang
    • 1
  • Bingyuan Wang
    • 2
    • 3
  • Yongcheng Ren
    • 2
    • 3
  • Yang Zhao
    • 2
    • 3
  • Dongsheng Hu
    • 1
    • 2
    Email author
  1. 1.The First Affiliated Hospital of Henan University of CMZhengzhouChina
  2. 2.Department of Preventive MedicineShenzhen University Health Science CenterShenzhenChina
  3. 3.Department of Epidemiology and Health StatisticsCollege of Public Health, Zhengzhou UniversityZhengzhouChina

Personalised recommendations